期刊文献+

Design and preparation of polyurethane-collagen/ heparin-conjugated polycaprolactone double-layer bionic small-diameter vascular graft and its preliminary animal tests 被引量:2

Design and preparation of polyurethane-collagen/ heparin-conjugated polycaprolactone double-layer bionic small-diameter vascular graft and its preliminary animal tests
原文传递
导出
摘要 Background People recently realized that it is important for artificial vascular biodegradable graft to bionically mimic the functions of the native vessel. In order to overcome the high risk of thrombosis and keep the patency in the clinical small-diameter vascular graft (SDVG) transplantation, a double-layer bionic scaffold, which can offer anticoagulation and mechanical strength simultaneously, was designed and fabricated via electrospinning technique. Methods Heparin-conjugated polycaprolactone (hPCL) and polyurethane (PU)-collagen type I composite was used as the inner and outer layers, respectively. The porosity and the burst pressure of SDVG were evaluated. Its biocompatibility was demonstrated by the 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide (MTT) test in vitro and subcutaneous implants in vivo respectively. The grafts of diameter 2.5 mm and length 4.0 cm were implanted to replace the femoral artery in Beagle dog model. Then, angiography was performed in the Beagle dogs to investigate the patency and aneurysm of grafts at 2, 4, and 8 weeks post-transplantation. After angiography, the patent grafts were explanted for histological analysis. Results The double-layer bionic SDVG meet the clinical mechanical demand. Its good biocompatibility was proven by cytotoxicity experiment (the cell's relative growth rates (RGR) of PU-collagen outer layer were 102.8%, 109.2% and 103.5%, while the RGR of hPCL inner layer were 99.0%, 100.0% and 98.0%, on days 1, 3, and 5, respectively) and the subdermal implants experiment in the Beagle dog. Arteriography showed that all the implanted SDVGs were patent without any aneurismal dilatation or obvious anastomotic stenosis at the 2nd, 4th, and 8th week after the operation, except one SDVG that failed at the 2nd week. Histological analysis and SEM showed that the inner layer was covered by new endothelial-like cells. Conclusion The double-layer bionic SDVG is a promising candidate as a replacement of native small-diameter vascular graft. Background People recently realized that it is important for artificial vascular biodegradable graft to bionically mimic the functions of the native vessel. In order to overcome the high risk of thrombosis and keep the patency in the clinical small-diameter vascular graft (SDVG) transplantation, a double-layer bionic scaffold, which can offer anticoagulation and mechanical strength simultaneously, was designed and fabricated via electrospinning technique. Methods Heparin-conjugated polycaprolactone (hPCL) and polyurethane (PU)-collagen type I composite was used as the inner and outer layers, respectively. The porosity and the burst pressure of SDVG were evaluated. Its biocompatibility was demonstrated by the 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide (MTT) test in vitro and subcutaneous implants in vivo respectively. The grafts of diameter 2.5 mm and length 4.0 cm were implanted to replace the femoral artery in Beagle dog model. Then, angiography was performed in the Beagle dogs to investigate the patency and aneurysm of grafts at 2, 4, and 8 weeks post-transplantation. After angiography, the patent grafts were explanted for histological analysis. Results The double-layer bionic SDVG meet the clinical mechanical demand. Its good biocompatibility was proven by cytotoxicity experiment (the cell's relative growth rates (RGR) of PU-collagen outer layer were 102.8%, 109.2% and 103.5%, while the RGR of hPCL inner layer were 99.0%, 100.0% and 98.0%, on days 1, 3, and 5, respectively) and the subdermal implants experiment in the Beagle dog. Arteriography showed that all the implanted SDVGs were patent without any aneurismal dilatation or obvious anastomotic stenosis at the 2nd, 4th, and 8th week after the operation, except one SDVG that failed at the 2nd week. Histological analysis and SEM showed that the inner layer was covered by new endothelial-like cells. Conclusion The double-layer bionic SDVG is a promising candidate as a replacement of native small-diameter vascular graft.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第7期1310-1316,共7页 中华医学杂志(英文版)
关键词 small-diameter vascular graft heparin-conjugated polycaprolactone double-layer scaffold BIONIC in vivo implant small-diameter vascular graft heparin-conjugated polycaprolactone double-layer scaffold bionic in vivo implant
  • 相关文献

参考文献2

二级参考文献13

  • 1Harenberg J.Is laboratory monitoring of low-molecularweight heparin therapy necessary? Yes.J Thromb Haemost 2004; 2:547-550.
  • 2Bounameaux H,de Moerloose P.Is laboratory monitoring of low molecular-weight heparin therapy necessary? No.J Thromb Haemost 2004; 2:551-554.
  • 3Milovic NM,Behr JR,Godin M,Hou CS,Payer KR,Chandrasekaran A,et al.Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.Proc Nail Acad Sci U S A 2006; 103:13374-13379.
  • 4Middeldorp S.Heparin:from animal organ extract to designer drug.Thromb Res 2008; 122:753-762.
  • 5Clem JR.Anti-factor Xa levels:when should they be used? S D Med 2006; 59:261-262.
  • 6Fergnson J J,Califf RM,Antman EM,Cohen M,Grines CL,Goodman S,et al.SYNERGY Trial Investigators.Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy:primary results of the SYNERGY randomized trial.JAMA 2004; 292:45-54.
  • 7White HD,Kleiman NS,Mahaffey KW,Lokhnygina Y,Pieper KS,Chiswell K,et al.Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin,Revascularization and Glycoprotein Ⅱb/Ⅲa Inhihitors (SYNERGY) trial.Am Heart J 2006; 52:1042-1050.
  • 8Blazing MA,de Lemos JA,White HD,Fox KA,Verheugt FW,Ardissino D,et al.Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin:a randomized controlled trial.JAMA 2004; 292:55-64.
  • 9Lepor NE.Anticoagnlation for acute coronary syndromes:from heparin to direct thrombin inhibitors.Rev Cardiovasc Med 2007; 8 Suppl 3:S9-S17.
  • 10Cavusoglu E,Lakhani M,Marmur JD.The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administraton.J Invasive Cardiol 2005; 17:416-421.

共引文献33

同被引文献5

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部